Arch Dermatol
-
Multicenter Study
The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma.
To describe the diagnostic performance of SolarScan (Polartechnics Ltd, Sydney, Australia), an automated instrument for the diagnosis of primary melanoma. ⋯ SolarScan is a robust diagnostic instrument for pigmented or partially pigmented melanocytic lesions of the skin. Preliminary data suggest that its performance is comparable or superior to that of a range of clinician groups. However, these findings should be confirmed in a formal clinical trial.
-
Multicenter Study
General anesthesia for pediatric dermatologic procedures: risks and complications.
To assess the safety and adverse events associated with the use of general anesthesia in children undergoing elective dermatologic procedures. ⋯ The use of general anesthesia for dermatologic procedures in a children's hospital setting appears safe, with a low rate of complications.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
To assess the efficacy and safety of a 24-week course of efalizumab. ⋯ At week 12, 26.6% of efalizumab-treated patients achieved PASI-75 and 58.5% achieved PASI-50. After 24 weeks of continuous efalizumab therapy, PASI responses increased: 43.8% of patients achieved PASI-75 and 66.6% achieved PASI-50. The percentage of patients who achieved an sPGA rating of minimal or clear increased from 25.7% to 35.9%. The mean percentage of improvement in all patient-reported outcomes (DLQI, itching scale, and PSA frequency and severity scores) at week 12 was maintained at week 24 (DLQI, 49.2%; itching scale, 42.2%; PSA frequency, 47.6%; PSA severity, 47.3%). There was a decline in overall reported adverse events from weeks 1 to 12 (80.4%) to weeks 13 to 24 (63.2%) without evidence of cumulative toxic effects. Conclusion Extending efalizumab treatment from 12 to 24 weeks leads to improved efficacy and maintenance of quality of life with no evidence of cumulative toxic effects noted in patients with moderate to severe chronic plaque psoriasis.
-
Letter Multicenter Study Clinical Trial
5% imiquimod cream for the treatment of large superficial basal cell carcinoma.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.
Photodynamic therapy (PDT) is increasingly used as a noninvasive treatment for nodular basal cell carcinoma (BCC), without a sound evidence base. ⋯ Methyl aminolevulinate PDT is an effective treatment for nodular BCC, and while there is a trend for higher recurrence with this modality, it conveys the advantage over surgery of better cosmesis.